Collectively, these findings underscore the involvement of Th2 cytokines—particularly IL-4 and IL-13—in PN pathogenesis and suggest that dupilumab may improve symptoms by disrupting the itch–scratch cycle [26,35,36,49,50]. This evidence concerns the gene IL13 and poikiloderma with neutropenia.